Alopecia associated with strontium ranelate use in a 62-year-old woman.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 22525979.
- Also identified by DOI 10.1007/s00198-012-1979-9.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Strontium ranelate is an effective drug that was developed for treating osteoporosis. Here, we report the case of a 62-year-old woman who developed headache and diffuse scalp hair loss 1 week after receiving strontium ranelate treatment for osteoporosis. The treatment was subsequently stopped because of the intractable headache. Nevertheless, the patient continued to lose hair for 6 weeks following treatment discontinuation. Histopathological analysis of scalp tissues revealed anagen effluvium. The patient's hair started regrowing slowly 2 months after treatment with strontium ranelate was discontinued.
Medical subject headings
- Alopecia
- Bone Density Conservation Agents
- Drug Eruptions
- Organometallic Compounds
- Osteoporosis, Postmenopausal
- Thiophenes